UBX - ユニティ―・バイオテクノロジ― （Unity Biotechnology Inc.）

Unity Biotechnology Inc. (NASDAQ:UBX) marked $2.46 per share on Tuesday, up from a previous closing price of $2.44. While Unity Biotechnology Inc. has overperformed by 0.82%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, UBX fell by -89.58%, with highs and lows ranging from $36.40 to […]

Unity Biotechnology press release (UBX): Q3 GAAP EPS of -$1.36 misses by $0.30.The company believes that current cash, cash equivalents, and marketable securities of $103.9M…

- Announced positive 24-week data in Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema; single injection led to statistically significant and clinically meaningful improvement in BCVA with favorable safety profile through six months -

Unity Biotechnology Inc. (NASDAQ:UBX) traded at $2.75 at close of the session on Tuesday, 11/01/22, made a downward move of -3.85% on its previous day’s price. Looking at the stock we see that its previous close was $2.86 and the beta (5Y monthly) reads 0.54 with the day’s price range being $2.67 – $3.74. In … Unity Biotechnology Inc. (NASDAQ: UBX)’s Loss Of -3.85% Profited Investors Read More »

Unity Biotechnology (UBX) stock is gaining on Tuesday after the company released results from a Phase 2 clinical trial of UBX1325.

Unity Biotechnology Inc. (NASDAQ:UBX) marked $2.46 per share on Tuesday, up from a previous closing price of $2.44. While Unity Biotechnology Inc. has overperformed by 0.82%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, UBX fell by -89.58%, with highs and lows ranging from $36.40 to […]

Unity Biotechnology press release (UBX): Q3 GAAP EPS of -$1.36 misses by $0.30.The company believes that current cash, cash equivalents, and marketable securities of $103.9M…

- Announced positive 24-week data in Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema; single injection led to statistically significant and clinically meaningful improvement in BCVA with favorable safety profile through six months -

Unity Biotechnology Inc. (NASDAQ:UBX) traded at $2.75 at close of the session on Tuesday, 11/01/22, made a downward move of -3.85% on its previous day’s price. Looking at the stock we see that its previous close was $2.86 and the beta (5Y monthly) reads 0.54 with the day’s price range being $2.67 – $3.74. In … Unity Biotechnology Inc. (NASDAQ: UBX)’s Loss Of -3.85% Profited Investors Read More »

Unity Biotechnology (UBX) stock is gaining on Tuesday after the company released results from a Phase 2 clinical trial of UBX1325.

In last trading session, Unity Biotechnology Inc. (NASDAQ:UBX) saw 0.74 million shares changing hands with its beta currently measuring 0.76. Company’s recent per share price level of $0.39 trading at -$0.01 or -3.19% at ring of the bell on the day assigns it a market valuation of $58.24M. That closing price of UBX’s stock is … Is Unity Biotechnology Inc. (NASDAQ:UBX) A Better Buy Than Others After A -83.60% Fall In This Year? Read More »

- Presentations from UNITY''s leadership team and fireside chat with retina expert Robert B. Bhisitkul, M.D., Ph.D., on Wednesday, October 12 from 8:00 a.m. to 9:30 a.m. ET - SOUTH SAN FRANCISCO, Calif., Oct. 11, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (NASDAQ: UBX ), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, tomorrow will host an Investor and Analyst Day with presentations highlighting the UBX1325 program, a novel Bcl-xL inhibitor for the treatment of age-related diseases of the eye, followed by a fireside chat with retina expert Robert Bhisitkul, M.D., Ph.D. Presentations include a review of the BEHOLD data in diabetic macular edema (DME), an overview of the recently added long-term extension arms to the Phase 2 ENVISION study in wet age-related macular degeneration (wAMD), as well as clinical development plans, near-term data milestones, and the latest research supporting the therapeutic approach of targeting senescent cells in diseased retinal tissue. "We''re encouraged by the momentum our ophthalmology program has garnered as UBX1325 advances through the clinic and is emerging as a potentially new class of medicine in DME and wAMD," said Anirvan Ghosh, Ph.D., chief executive officer of UNITY. "Based on the potential efficacy we''ve already seen in patients with DME up to 18 weeks following a single injection of UBX1325 in our ongoing Phase 2 BEHOLD study, we are exploring additional indications where new treatment options are much needed.

Bearish sentiment continues to have a strong impact on the U.S. stock market, and the healthcare sector has suffered as well, with a year-to-date decline of more than 15%. Some healthcare stocks have performed well while others have not. However, underperforming healthcare stocks could provide interesting investment opportunities. Two stocks to consider in this regard are Unity Biotechnology (NASDAQ: UBX) and Aerie Pharma (NASDAQ: AERI). The former shows high upside potential, while the latter, barring an acquisition by Alcon (NYSE: ALC), isn''t as promising.

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Breathtaking stocks: Unity Biotechnology, Inc. (NASDAQ:UBX -0.95%), National CineMedia, Inc. (NASDAQ:NCMI -4.68%) appeared first on Stocks Equity .

A share of Unity Biotechnology Inc. (NASDAQ:UBX) closed at $0.45 per share on Monday, down from $0.47 day before. While Unity Biotechnology Inc. has underperformed by -2.77%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, UBX fell by -85.08%, with highs and lows ranging from $3.64 […]